Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...

Alec­tor re­port­ed a Phase 2 fail­ure for an Ab­b­Vie-part­nered Alzheimer’s pro­gram Mon­day af­ter­noon and said it will ...

Shares of Alector tumbled in after-hours trading after the company said its Alzheimer drug candidate, AL002, failed to meet its phase 2 primary endpoint of slowing clinical progression of the disease.

Investing.com -- Alector Inc.宣布，其用于早期阿尔茨海默症治疗的AL002药物的二期临床试验未能达到减缓疾病进展的主要目标。受此消息影响，该公司股价在盘后交易中暴跌32%。 这家生物制药公司表示，由于试验未能达到主要终点，将终止AL002的长期延伸研究。针对这一发展，Alector还透露计划裁减约17%的员工。

南旧金山 - 专注于神经退行性疾病的生物科技公司Alector, Inc.

As of September 30, 2024, Alector has $457.2 million in cash, cash equivalents, and investments, which the company continues ...

Alector ( (ALEC) ) has released its Q3 earnings. Here is a breakdown of the information Alector presented to its investors.Don't Miss our Black ...

There are approx. 80+ key companies which are developing the therapies for Dementia Associated With Alzheimer's Disease. The companies which have their Dementia Associated With Alzheimer's Disease ...

Vitalli Bio ends Daewoong deal, Alector receives $50M Hercules Capital loan, Bavarian Nordic gets $340M vaccine orders, Nuvectis Pharma reports disappointing trial data, Flashpoint partners with Saudi ...

Alector, a clinical-stage biotechnology company pioneering immuno-neurology, entered into a debt financing agreement with Hercules Capital for up to $50 million. Under the terms of the agreement, ...

Alector ( (ALEC) ) has provided an update. Alector, a clinical-stage biotechnology company, has secured a $50 million credit facility from ...

Hercules Capital Provides Flexible Credit Facility Up to $50MM to Alector ...